The trademark application Dxvira was filed by Sana Pharma Medical AS, a corporation established under the laws of the Kingdom of Norway (the "Applicant"). The application was published for oppositions on June 17, 2021, and it was registered by office on September 24, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).